230 related articles for article (PubMed ID: 24699306)
21. The Heparanase Inhibitor PG545 Attenuates Colon Cancer Initiation and Growth, Associating with Increased p21 Expression.
Singh P; Blatt A; Feld S; Zohar Y; Saadi E; Barki-Harrington L; Hammond E; Ilan N; Vlodavsky I; Chowers Y; Half E
Neoplasia; 2017 Mar; 19(3):175-184. PubMed ID: 28147305
[TBL] [Abstract][Full Text] [Related]
22. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis.
Edovitsky E; Elkin M; Zcharia E; Peretz T; Vlodavsky I
J Natl Cancer Inst; 2004 Aug; 96(16):1219-30. PubMed ID: 15316057
[TBL] [Abstract][Full Text] [Related]
23. Heparanase: busy at the cell surface.
Fux L; Ilan N; Sanderson RD; Vlodavsky I
Trends Biochem Sci; 2009 Oct; 34(10):511-9. PubMed ID: 19733083
[TBL] [Abstract][Full Text] [Related]
24. CXCL10 can inhibit endothelial cell proliferation independently of CXCR3.
Campanella GS; Colvin RA; Luster AD
PLoS One; 2010 Sep; 5(9):e12700. PubMed ID: 20856926
[TBL] [Abstract][Full Text] [Related]
25. Cytokine-induced apoptosis inhibitor 1 inhibits the growth and proliferation of multiple myeloma.
Wang X; Pan J; Li J
Mol Med Rep; 2015 Aug; 12(2):2056-62. PubMed ID: 25901506
[TBL] [Abstract][Full Text] [Related]
26. Heparanase 2 Attenuates Head and Neck Tumor Vascularity and Growth.
Gross-Cohen M; Feld S; Doweck I; Neufeld G; Hasson P; Arvatz G; Barash U; Naroditsky I; Ilan N; Vlodavsky I
Cancer Res; 2016 May; 76(9):2791-801. PubMed ID: 27013193
[TBL] [Abstract][Full Text] [Related]
27. Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis.
Goldshmidt O; Zcharia E; Abramovitch R; Metzger S; Aingorn H; Friedmann Y; Schirrmacher V; Mitrani E; Vlodavsky I
Proc Natl Acad Sci U S A; 2002 Jul; 99(15):10031-6. PubMed ID: 12097647
[TBL] [Abstract][Full Text] [Related]
28. Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression.
Cohen-Kaplan V; Doweck I; Naroditsky I; Vlodavsky I; Ilan N
Cancer Res; 2008 Dec; 68(24):10077-85. PubMed ID: 19074873
[TBL] [Abstract][Full Text] [Related]
29. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation.
Zetser A; Bashenko Y; Edovitsky E; Levy-Adam F; Vlodavsky I; Ilan N
Cancer Res; 2006 Feb; 66(3):1455-63. PubMed ID: 16452201
[TBL] [Abstract][Full Text] [Related]
30. Heparanase expression of glioma in human and animal models.
Hong X; Nelson KK; deCarvalho AC; Kalkanis SN
J Neurosurg; 2010 Aug; 113(2):261-9. PubMed ID: 19835469
[TBL] [Abstract][Full Text] [Related]
31. A xenograft model reveals that PU.1 functions as a tumor suppressor for multiple myeloma in vivo.
Nishimura N; Endo S; Ueno S; Ueno N; Tatetsu H; Hirata S; Hata H; Komohara Y; Takeya M; Mitsuya H; Okuno Y
Biochem Biophys Res Commun; 2017 May; 486(4):916-922. PubMed ID: 28347818
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype.
Ramani VC; Vlodavsky I; Ng M; Zhang Y; Barbieri P; Noseda A; Sanderson RD
Matrix Biol; 2016 Sep; 55():22-34. PubMed ID: 27016342
[TBL] [Abstract][Full Text] [Related]
33. Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells.
Nadir Y; Brenner B; Gingis-Velitski S; Levy-Adam F; Ilan N; Zcharia E; Nadir E; Vlodavsky I
Thromb Haemost; 2008 Jan; 99(1):133-41. PubMed ID: 18217145
[TBL] [Abstract][Full Text] [Related]
34. Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype.
Purushothaman A; Hurst DR; Pisano C; Mizumoto S; Sugahara K; Sanderson RD
J Biol Chem; 2011 Sep; 286(35):30377-30383. PubMed ID: 21757697
[TBL] [Abstract][Full Text] [Related]
35. Heparanase and Chemotherapy Synergize to Drive Macrophage Activation and Enhance Tumor Growth.
Bhattacharya U; Gutter-Kapon L; Kan T; Boyango I; Barash U; Yang SM; Liu J; Gross-Cohen M; Sanderson RD; Shaked Y; Ilan N; Vlodavsky I
Cancer Res; 2020 Jan; 80(1):57-68. PubMed ID: 31690669
[TBL] [Abstract][Full Text] [Related]
36. Downregulation of heparanase by RNA interference inhibits invasion and tumorigenesis of hepatocellular cancer cells in vitro and in vivo.
Xiong Z; Lü MH; Fan YH; Cao YL; Hu CJ; Wu YY; Wang SM; Luo G; Fang DC; Li C; Yang SM
Int J Oncol; 2012 May; 40(5):1601-9. PubMed ID: 22267022
[TBL] [Abstract][Full Text] [Related]
37. Heparanase inhibits osteoblastogenesis and shifts bone marrow progenitor cell fate in myeloma bone disease.
Ruan J; Trotter TN; Nan L; Luo R; Javed A; Sanderson RD; Suva LJ; Yang Y
Bone; 2013 Nov; 57(1):10-7. PubMed ID: 23895995
[TBL] [Abstract][Full Text] [Related]
38. C-kit ligand (SCF) in human multiple myeloma cells.
Lemoli RM; Fortuna A
Leuk Lymphoma; 1996 Feb; 20(5-6):457-64. PubMed ID: 8833403
[TBL] [Abstract][Full Text] [Related]
39. Down-regulation of heparanase leads to the inhibition of invasion and proliferation of A549 cells in vitro and in vivo.
Chen Z; Zhu L; Li X; Tian H; Fang Y; Liu H; Li S; Li L; Yue W; Li W
Acta Biochim Biophys Sin (Shanghai); 2013 Mar; 45(3):188-93. PubMed ID: 23241438
[TBL] [Abstract][Full Text] [Related]
40. Heparanase: From basic research to therapeutic applications in cancer and inflammation.
Vlodavsky I; Singh P; Boyango I; Gutter-Kapon L; Elkin M; Sanderson RD; Ilan N
Drug Resist Updat; 2016 Nov; 29():54-75. PubMed ID: 27912844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
